Back to mobile site

Avadel Pharma (AVDL) Tops Q2 EPS by 14c, Beats on Revenues; Lowers FY17 Revenue Guidance Below Consensus

August 8, 2017 7:35 AM EDT

Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of $0.19, $0.14 better than the analyst estimate of $0.05. Revenue for the quarter came in at $46.13 million versus the consensus estimate of $45.13 million.

2017 Guidance

As a result of continued pricing pressure in the ephedrine market and increased competition in the neostigmine market, the Company is revising its revenue guidance to between $165 and $175 million, compared to previous guidance of between $170 and $185 million.

As a result of lower than expected spending during the first two quarters of 2017, R&D is now expected to be in the range of $30 to $40 million compared to previous guidance of $40 to $50 million. Diluted adjusted EPS is unchanged from previous guidance of $0.30 to $0.45.

GUIDANCE:

Avadel Pharma sees FY2017 EPS of $0.30-$0.45, versus the consensus of $0.54. Avadel Pharma sees FY2017 revenue of $165-175 million, versus the consensus of $177.26 million.

Highlights Include:

  • Total revenues for the second quarter 2017 were $46.3 million, compared to $38.9 million in the second quarter 2016.
  • GAAP net income for the second quarter of 2017 was $28.9 million, or $0.68 per diluted share, compared to GAAP net loss of $20.0 million, or $0.48 per diluted share, in the second quarter of 2016.
  • Adjusted net income for the second quarter of 2017 was $8.2 million, or $0.19 per diluted share, compared to an adjusted net loss of $1.0 million, or $0.02 per diluted share, in the second quarter of 2016.(1)
  • Cash and marketable securities at June 30, 2017 were $173.8 million, up from $154.2 million at December 31, 2016.
  • Cash used for share repurchases totaled $13.1 million for the six months ended June 30, 2017.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Guidance, Management Comments

Related Entities

Earnings